SEC Form 4 · accession 0000899243-17-028846
Spero Therapeutics, Inc. · SPRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ankit Mahadevia
Officer — See Remarks · Director
Period of report
Dec 13, 2017
Accepted (ET)
Dec 15, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001701108
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $11.63 | Dec 13, 2017 | A | 125,079 | A | — | Dec 12, 2027 | Common Stock | 125,079 | 125,079 | D |
Explanation of responses
- F1The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Remarks
Chief Executive Officer and President